(Q45044609)

8 December 2017

Relative stability of meningococcal serogroup A and X polysaccharides (English)

1 reference

8 December 2017

1 reference

9

1 reference

8 December 2017

F Berti

1

1 reference

8 December 2017

M R Romano

2

1 reference

8 December 2017

F Micoli

3

1 reference

8 December 2017

V Pinto

4

1 reference

8 December 2017

E Cappelletti

5

1 reference

8 December 2017

M Gavini

6

1 reference

8 December 2017

D Proietti

7

1 reference

8 December 2017

G Pluschke

8

1 reference

8 December 2017

P Costantino

10

1 reference

8 December 2017

language of work or name

English

0 references

publication date

22 August 2012

1 reference

8 December 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

8 December 2017

30

1 reference

8 December 2017

45

1 reference

8 December 2017

6409-6415

1 reference

Global epidemiology of meningococcal disease.

8 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Vaccine introduction. The beginning of the end for Africa's devastating meningitis outbreaks?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Prevalence of meningococcal serogroups and description of three new groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Clonal groupings in serogroup X Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Infections by Neisseria meningitidis serogroup X in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.021

10.1016/J.VACCINE.2012.08.021

7 January 2021

Identifiers

DOI

1 reference

8 December 2017

1 reference